Leishmaniasis: current situation and new perspectives
- PMID: 15225981
- DOI: 10.1016/j.cimid.2004.03.004
Leishmaniasis: current situation and new perspectives
Abstract
Leishmaniasis represents a complex of diseases with an important clinical and epidemiological diversity. Visceral leishmaniasis (VL) is of higher priority than cutaneous leishmaniasis (CL) as it is a fatal disease in the absence of treatment. Anthroponotic VL foci are of special concern as they are at the origin of frequent and deathly epidemics (e.g. Sudan). Leishmaniasis burden remains important: 88 countries, 350 million people at risk, 500,000 new cases of VL per year, 1-1.5 million for CL and DALYs: 2.4 millions. Most of the burden is concentrated on few countries which allows clear geographic priorities. Leishmaniasis is still an important public health problem due to not only environmental risk factors such as massive migrations, urbanisation, deforestation, new irrigation schemes, but also to individual risk factors: HIV, malnutrition, genetic, etc em leader Leishmaniasis is part of those diseases which still requires improved control tools. Consequently WHO/TDR research for leishmaniasis has been more and more focusing on the development of new tools such as diagnostic tests, drugs and vaccines. The ongoing effort has already produced significant results. The newly available control tools should allow a scaling up of control activities in priority areas. In anthroponotic foci, the feasibility of getting a strong impact on mortality, morbidity and transmission, is high.
Similar articles
-
Leishmaniasis and poverty.Trends Parasitol. 2006 Dec;22(12):552-7. doi: 10.1016/j.pt.2006.09.004. Epub 2006 Oct 4. Trends Parasitol. 2006. PMID: 17023215
-
[Monitoring of canine leishmaniasis in northern Italy: an update from a scientific network].Parassitologia. 2004 Jun;46(1-2):193-7. Parassitologia. 2004. PMID: 15305715 Review. Italian.
-
Human leishmaniases: epidemiology and public health aspects.World Health Stat Q. 1992;45(2-3):267-75. World Health Stat Q. 1992. PMID: 1462660
-
Leishmaniasis chemotherapy--challenges and opportunities.Clin Microbiol Infect. 2011 Oct;17(10):1478-83. doi: 10.1111/j.1469-0691.2011.03630.x. Clin Microbiol Infect. 2011. PMID: 21933306 Review.
-
Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan.Drug Dev Ind Pharm. 2010 Nov;36(11):1312-9. doi: 10.3109/03639041003796648. Drug Dev Ind Pharm. 2010. PMID: 20545513 Review.
Cited by
-
A putative Leishmania DNA polymerase theta protects the parasite against oxidative damage.Nucleic Acids Res. 2016 Jun 2;44(10):4855-70. doi: 10.1093/nar/gkw346. Epub 2016 Apr 29. Nucleic Acids Res. 2016. PMID: 27131366 Free PMC article.
-
Antileishmanial and cytotoxic effects of essential oil and methanolic extract of Myrtus communis L.Korean J Parasitol. 2015 Feb;53(1):21-7. doi: 10.3347/kjp.2015.53.1.21. Epub 2015 Feb 27. Korean J Parasitol. 2015. PMID: 25748705 Free PMC article.
-
Triethyl phosphine decorated cerium oxide nanoparticles exhibit selective killing of the unicellular protozoan parasite Leishmania donovani.3 Biotech. 2023 Dec;13(12):413. doi: 10.1007/s13205-023-03813-7. Epub 2023 Nov 22. 3 Biotech. 2023. PMID: 38009165 Free PMC article.
-
Naturally occurring culturable aerobic gut flora of adult Phlebotomus papatasi, vector of Leishmania major in the Old World.PLoS One. 2012;7(5):e35748. doi: 10.1371/journal.pone.0035748. Epub 2012 May 22. PLoS One. 2012. PMID: 22629302 Free PMC article.
-
An Eco-Epidemiological Study on Zoonotic Cutaneous Leishmaniasis in Central Iran.Iran J Public Health. 2021 Feb;50(2):350-359. doi: 10.18502/ijph.v50i2.5350. Iran J Public Health. 2021. PMID: 33747999 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources